Results 191 to 200 of about 824,404 (357)

A synthetic benzoxazine dimer derivative targets c‐Myc to inhibit colorectal cancer progression

Molecular Oncology, EarlyView.
Benzoxazine dimer derivatives bind to the bHLH‐LZ region of c‐Myc, disrupting c‐Myc/MAX complexes, which are evaluated from SAR analysis. This increases ubiquitination and reduces cellular c‐Myc. Impairing DNA repair mechanisms is shown through proteomic analysis.
Nicharat Sriratanasak, Bodee Nutho, Worawat Wattanathana, Narumon Phaonakrop, Bunnatut Panasawatwong, Katharina Erlenbach‐Wuensch, Sittiruk Roytrakul, Regine Schneider‐Stock, Pithi Chanvorachote   +8 more
wiley   +1 more source

Latinas and HIV/AIDS Risk Factors: Implications for Harm Reduction Strategies

, 2004
Ruth Enid Zambrana, Llewellyn J. Cornelius, Stephanie Sims Boykin, Debbie Salas Lopez   +3 more
openalex   +2 more sources

The power few: experimental criminology and the reduction of harm [PDF]

, 2007
Lawrence W. Sherman
openalex   +1 more source

Adaptaquin is selectively toxic to glioma stem cells through disruption of iron and cholesterol metabolism

Molecular Oncology, EarlyView.
Adaptaquin selectively kills glioma stem cells while sparing differentiated brain cells. Transcriptomic and proteomic analyses show Adaptaquin disrupts iron and cholesterol homeostasis, with iron chelation amplifying cytotoxicity via cholesterol depletion, mitochondrial dysfunction, and elevated reactive oxygen species.
Adrien M. Vaquié, Davod R. Shah, Eliane E. S. Brechbühl, Michael McNicholas, Zhaoyang Xu, John H. Stockley, Laura Morcom, Diana Gold Diaz, Gemma C. Girdler, Rachel V. Seear, Gabriel Balmus, Rajiv R. Ratan, Harry Bulstrode, James A. Nathan, Manav Pathania, Kevin M. Brindle, David H. Rowitch   +16 more
wiley   +1 more source

Harm reduction approaches for the use of benzodiazepines: a scoping review. [PDF]

Harm Reduct J
Morrison C, Natale I, Branchflower A, Harvey C, Lundin RM.   +4 more
europepmc   +1 more source

Scottish report on hepatitis C and injecting practices has implications for policy and harm reduction strategies

, 2004
A. Taylor, Anne Fleming, Jeanne Rutherford, David Goldberg   +3 more
openalex   +1 more source

Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users [PDF]

, 2007
Charlotte van den Berg, Colette Smit, Giel van Brussel, Roel A. Coutinho, Maria Prins   +4 more
openalex   +1 more source

HARM REDUCTION—WHAT IS IT? [PDF]

Addiction, 2007
openaire   +3 more sources

Harm Reduction: A Research Agenda [PDF]

Health Care Analysis, 2020
Shannon Dea, Daniel Weinstock
openaire   +2 more sources

Patient‐specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity

Molecular Oncology, EarlyView.
This study integrates transcriptomic profiling of matched tumor and healthy tissues from 32 colorectal cancer patients with functional validation in patient‐derived organoids, revealing dysregulated metabolic programs driven by overexpressed xCT (SLC7A11) and SLC3A2, identifying an oncogenic cystine/glutamate transporter signature linked to ...
Marco Strecker, Keren Zohar, Martin Böttcher, Thomas Wartmann, Henry Freudenstein, Maximilian Doelling, Mihailo Andric, Wenjie Shi, Or Kakhlon, Katrin Hippe, Beatrix Jahnke, Dimitrios Mougiakakos, Franziska Baenke, Daniel Stange, Roland S. Croner, Michal Linial, Ulf D. Kahlert   +16 more
wiley   +1 more source